Last reviewed · How we verify
NCT04156100
A Study in Subjects With Advanced Solid Tumors
Phase 1 trial testing AGEN1223 in Advanced Solid Tumor in 19 participants. Terminated before completion.
8 April 2021
Quick facts
| Lead sponsor | Agenus Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 10 December 2019 |
| Primary completion | 8 April 2021 |
| Estimated completion | 29 September 2021 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- AGEN1223 — full drug profile →
- AGEN1223 and balstilimab — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
Agenus Inc. — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.
Arasanz H, Chocarro L, Fernández-Rubio L, Blanco E, et al · · 2023 · cited 6× · PMID 37373003 · DOI 10.3390/ijms24129855
Verify or expand the search:
- PubMed search for NCT04156100
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Agenus Inc. trials
Trials by the same sponsor.
- NCT05630183 — A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer · Phase 2 · active not recruiting
- NCT05377528 — Study of AGEN1571 in Participants With Advanced Solid Tumors · Phase 1 · completed
- NCT05025085 — A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors · Phase 1 · completed
- NCT05033132 — A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer · Phase 2 · withdrawn
- NCT04943627 — Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) · Phase 3 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04156100 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Agenus Inc.
- Last refreshed: 3 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156100.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing